A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

NCT05624918 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Adenocarcinoma
Resectable Pancreatic Cancer

Interventions

DRUG: Nab paclitaxel
DRUG: Gemcitabine
DEVICE: NovoTTF-200T(P)

Sponsor

Ashish Manne

Collaborators

[object Object]
[object Object]